A checklist for managed access programmes for reimbursement co‐designed by Canadian patients and caregivers

INTRODUCTION: Reimbursement decisions on orphan drugs carry significant uncertainty, and as the amount increases, so does the risk of making a wrong decision, where harms outweigh benefits. Consequently, patients often face limited access to orphan drugs. Managed access programmes (MAPs) are a mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Andrea, Menon, Devidas, Street, Jackie, Al‐Hertani, Walla, Stafinski, Tania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250858/
https://www.ncbi.nlm.nih.gov/pubmed/29624799
http://dx.doi.org/10.1111/hex.12690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250858/
https://www.ncbi.nlm.nih.gov/pubmed/29624799
http://dx.doi.org/10.1111/hex.12690

Ejemplares similares